UPDATES: NCCN Guidelines® and NCCN Compendium®
NCCN Flash Update sent January 17, 2014
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Chronic Myelogenous Leukemia. These NCCN Guidelines® are currently available as Version 3.2014.
- A new page was added to the Guidelines for the Management of Cytogenetic or Hematologic Resistance to TKIs.
- This page delineates subsequent therapy options based on previous treatment and selected mutations.
- Based on the revised FDA labeling, ponatinib is included as a treatment option for patients with T315I mutation and for patients who have failed multiple TKIs.
- The Discussion section has been updated to reflect the changes in the algorithm.
*For your reference, the announcement of the previous update (Version 2.2014) to the NCCN Guidelines for CML, distributed on November 4, 2013, is included below:
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Chronic Myelogenous Leukemia (CML). These NCCN Guidelines® are currently available as Version 2.2014.
Following the Drug Safety Communication issued October 31, 2013 by the U.S. Food and Drug Administration (FDA) regarding the safety issues with ponatinib (increased frequency of blood clots and narrowing of blood vessels), the agent has been removed as a treatment option for patients with CML until further discussion by the NCCN CML Guidelines Panel.
For the complete updated versions of the NCCN Guidelines, the NCCN Compendium®, and the NCCN Chemotherapy Order Templates (NCCN Templates®), please visit NCCN.org.
To access the NCCN Biomarkers Compendium™, please visit NCCN.org/biomarkers.
To view the NCCN Guidelines for Patients®, please visit NCCN.com/patients.
Free NCCN Guidelines apps for iPhone, iPad, and Android tablets are now available! Visit NCCN.org/apps.